Jpmorgan Chase & CO Krystal Biotech, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.23 Trillion
  • Q4 2024

A detailed history of Jpmorgan Chase & CO transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 151,835 shares of KRYS stock, worth $23.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
151,835
Previous 127,901 18.71%
Holding current value
$23.3 Million
Previous $23.3 Million 2.27%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025
BUY
$156.64 - $199.61 $3.75 Million - $4.78 Million
23,934 Added 18.71%
151,835 $23.8 Million
Q3 2024

Dec 26, 2024
SELL
$174.7 - $213.66 $6.28 Million - $7.68 Million
-35,923 Reduced 21.93%
127,901 $23.3 Million
Q3 2024

Nov 08, 2024
SELL
$174.7 - $213.66 $6.28 Million - $7.68 Million
-35,923 Reduced 21.93%
127,901 $23.3 Million
Q2 2024

Dec 26, 2024
BUY
$153.12 - $183.64 $5.5 Million - $6.6 Million
35,923 Added 28.09%
163,824 $30.1 Million
Q2 2024

Aug 12, 2024
SELL
$153.12 - $183.64 $1.73 Million - $2.08 Million
-11,302 Reduced 6.45%
163,824 $30.1 Million
Q1 2024

Dec 26, 2024
BUY
$108.01 - $179.35 $5.1 Million - $8.47 Million
47,225 Added 36.92%
175,126 $31.2 Million
Q1 2024

May 10, 2024
SELL
$108.01 - $179.35 $4.15 Million - $6.89 Million
-38,393 Reduced 17.98%
175,126 $31.2 Million
Q4 2023

Dec 26, 2024
BUY
$96.0 - $128.29 $8.22 Million - $11 Million
85,618 Added 66.94%
213,519 $26.5 Million
Q4 2023

Feb 12, 2024
SELL
$96.0 - $128.29 $765,504 - $1.02 Million
-7,974 Reduced 3.6%
213,519 $26.5 Million
Q3 2023

Nov 14, 2023
SELL
$108.51 - $130.22 $1.98 Million - $2.38 Million
-18,290 Reduced 7.63%
221,493 $25.7 Million
Q2 2023

Aug 11, 2023
BUY
$78.48 - $130.32 $107,831 - $179,059
1,374 Added 0.58%
239,783 $28.2 Million
Q1 2023

May 18, 2023
BUY
$72.39 - $84.27 $1.95 Million - $2.27 Million
26,936 Added 12.74%
238,409 $19.1 Million
Q1 2023

May 11, 2023
SELL
$72.39 - $84.27 $1.92 Million - $2.23 Million
-26,464 Reduced 11.12%
211,473 $16.9 Million
Q4 2022

Feb 13, 2023
SELL
$63.14 - $79.9 $300,293 - $380,004
-4,756 Reduced 1.96%
237,937 $18.8 Million
Q3 2022

Nov 14, 2022
SELL
$64.85 - $82.4 $1.03 Million - $1.31 Million
-15,874 Reduced 6.14%
242,693 $16.9 Million
Q2 2022

Aug 11, 2022
BUY
$48.93 - $73.47 $34,544 - $51,869
706 Added 0.27%
258,567 $17 Million
Q1 2022

May 11, 2022
BUY
$51.99 - $72.11 $3.03 Million - $4.2 Million
58,228 Added 29.17%
257,861 $17.2 Million
Q4 2021

Feb 10, 2022
SELL
$39.81 - $88.24 $986,730 - $2.19 Million
-24,786 Reduced 11.04%
199,633 $14 Million
Q3 2021

Nov 12, 2021
BUY
$52.01 - $71.77 $11.7 Million - $16.1 Million
224,419 New
224,419 $11.7 Million

About Krystal Biotech, Inc.

KRYS Quotes by TradingView
  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $3.93B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email